Can a tracer that hunts unstable iron light up hidden tumors?

NCT ID NCT06942104

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This phase 1 trial is testing whether a new imaging tracer called 18F-TRX can safely and effectively detect solid tumors using PET scans. The tracer targets unstable iron levels, which are often elevated in cancerous tissue. Adults with advanced solid tumors, including certain prostate, kidney, and brain cancers, will receive the tracer and undergo PET/CT imaging. The study aims to see if this approach can clearly visualize tumors and help guide future cancer diagnosis.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
an experimental PET imaging tracer called 18F-TRX (Fluorine F 18 TRX)
What this could lead to
If successful, this could provide a new way to detect and visualize a wide range of solid tumors using PET scans, potentially improving cancer diagnosis and monitoring.
What could go wrong
This is an early phase 1 trial with a small number of participants, so safety and effectiveness are not yet established. The tracer may not reliably distinguish tumors from healthy tissue.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of California, San Francisco

    RECRUITING

    San Francisco, California, 94143, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.